Martyré M C, Wietzerbin J
Unité 365 INSERM, Institut Curie, Section de Biologie, France.
Br J Haematol. 1994 Feb;86(2):244-52. doi: 10.1111/j.1365-2141.1994.tb04722.x.
Interferon-alpha (IFN-alpha) treatment has been shown to be highly effective in inhibiting human megakaryocytopoiesis and controlling thrombocytosis in patients with myeloproliferative disorders. These observations suggest that IFN-alpha might play some role in the biological feature of the megakaryocytic lineage and led us to investigate the presence of specific receptors for IFN-alpha on human megakaryocytic cells, i.e. the Dami cell line, and to study the regulation of their expression. Our study demonstrates that [125I]-recombinant human IFN-alpha ([125I]rHu-IFN-alpha) binds to high-affinity specific receptor on these cells. Scatchard analysis of binding data indicates the presence of homogeneous binding sites estimated in the range of 3000-5000, with an apparent equilibrium dissociation constant, Kd, of 1-2 x 10(-9) M. Also, [125I]rHuIFN-alpha binding capacity decreased in Dami cells incubated with unlabelled rHuIFN-alpha. This down-regulation which was dose-dependent appeared to result from a reduction of IFN-alpha cell surface receptors and was observed at doses that elicited antiproliferative effects in Dami cells. Cross-linking of [125I]rHuIFN-alpha to Dami membrane proteins using a bifunctional reagent yielded to a radioactive complex of approximately 150,000 kD on SDS-PAGE. Furthermore, in response to PMA, which induces the differentiation/maturation of the Dami cells as evaluated by surface marker and ploidy analysis, a 3-fold increase of the number of specific membrane receptors for IFN-alpha was observed, without any modification of either the affinity or the M(r) value of the cross-linked complex. Such an increase appeared to be restricted to IFN-alpha receptors; actually it was not observed in [125I]IFN-gamma binding experiments. Transcript analysis indicated that down-regulation and increased expression of the IFN-alpha receptor after PMA treatment are post-transcriptional events.
干扰素-α(IFN-α)治疗已被证明在抑制骨髓增殖性疾病患者的人类巨核细胞生成和控制血小板增多方面非常有效。这些观察结果表明,IFN-α可能在巨核细胞系的生物学特性中发挥某种作用,并促使我们研究人类巨核细胞(即达米细胞系)上IFN-α特异性受体的存在情况,并研究其表达的调节。我们的研究表明,[125I]重组人IFN-α([125I]rHu-IFN-α)与这些细胞上的高亲和力特异性受体结合。结合数据的Scatchard分析表明存在均匀的结合位点,估计范围为3000 - 5000个,表观平衡解离常数Kd为1 - 2×10(-9)M。此外,在用未标记的rHu-IFN-α孵育的达米细胞中,[125I]rHuIFN-α的结合能力下降。这种剂量依赖性的下调似乎是由于IFN-α细胞表面受体减少所致,并且在引起达米细胞抗增殖作用的剂量下观察到。使用双功能试剂将[125I]rHuIFN-α与达米细胞膜蛋白交联,在SDS-PAGE上产生了约150,000 kD的放射性复合物。此外,通过表面标志物和倍性分析评估,佛波酯(PMA)可诱导达米细胞分化/成熟,在此情况下观察到IFN-α特异性膜受体数量增加了3倍,而交联复合物的亲和力或相对分子质量(M(r))值均未发生任何改变。这种增加似乎仅限于IFN-α受体;实际上,在[125I]IFN-γ结合实验中未观察到这种情况。转录分析表明,PMA处理后IFN-α受体的下调和表达增加是转录后事件。